Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 111 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gadolinium Clear all
Completed Not applicable Interventional

An Evaluation Of The Novel TRAMINER Sequence By Comparison To Late Gadolinium Enhancement Images

NCT02727725
View directory record Official record
Conditions
Myocardial Fibrosis, Cardiovascular Disease
Interventions
Traminer MRI Sequence
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Sep 9, 2026, 5:22 AM EDT
Withdrawn No phase listed Observational

QSM and Regional DCE MRI Permeability Using GOCART Technique

NCT03091803
View directory record Official record
Conditions
Intracranial Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadoterate Meglumine, Magnetic Resonance Imaging
Device · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 4 Interventional

A Pilot Investigation Detecting Cryoablation Scar by 3D Late Gadolinium Enhancement

NCT02875730
View directory record Official record
Conditions
Atrial Fibrillation, Cryoablation
Interventions
Pulse Sequence, CMRI
Procedure
Lead sponsor
Aspire Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

NCT00096837
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Motexafin Gadolinium Injection
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 7, 2006 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 3 Interventional

Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases

NCT00003563
View directory record Official record
Conditions
Metastatic Cancer
Interventions
WBRT, MGd
Radiation · Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
31
States / cities
Greenbrae, California • Los Angeles, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Not applicable Interventional Results available

Long-Term Retention of Gadolinium in Bone

NCT01853163
View directory record Official record
Conditions
Focus: Long-term Retention of Gadolinium-based Contrast Agent
Interventions
Gadolinium analysis in bone and tissue samples
Procedure
Lead sponsor
Navitas Life Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 3 Interventional

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

NCT00054795
View directory record Official record
Conditions
Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Metastases, Neoplasm
Interventions
Motexafin Gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Sep 9, 2026, 5:22 AM EDT
Completed No phase listed Observational

Pilot Study of Cardiac MR in Patients With Muscular Dystrophy

NCT02921321
View directory record Official record
Conditions
Muscular Dystrophies, Cardiac Fibrosis, Genetic Diseases, Inborn, Musculoskeletal Diseases
Interventions
Not listed
Lead sponsor
Children's National Research Institute
Other
Eligibility
6 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 9, 2026, 5:22 AM EDT
Completed No phase listed Observational

Infiltration of Gadolinium Injection in Brain MR Scans Using Artificial Intelligence

NCT05235646
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Sep 9, 2026, 5:22 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System

NCT03331380
View directory record Official record
Conditions
CAD
Interventions
MRI scan - obj 1, MRI scans - obj 2, MRI scans - obj 3, MRI scans - obj 4
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
2,950 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Not applicable Interventional

Identification of Adverse Plaque Characteristics by Coronary MR Angiography

NCT01986868
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary MR Angiography (CMRA)
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 9, 2026, 5:22 AM EDT
Completed No phase listed Observational

Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography

NCT03910114
View directory record Official record
Conditions
Magnetic Resonance Imaging Contrast Agents
Interventions
Magnevist, Dotarem, Gadovist
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
500 participants
Timeline
1990 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 9, 2026, 5:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL

NCT00089284
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma (NHL)
Interventions
Rituxan, motexafin gadolinium, 111Indium-Zevalin and 90Yttrium-Zevalin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 9, 2026, 5:22 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

NCT03325166
View directory record Official record
Conditions
Lung Carcinoma Metastatic in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pembrolizumab
Drug · Other · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

Motexafin Gadolinium With MRI-Guided Surgery in Treating Patients With High-Grade Gliomas

NCT00003410
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
motexafin gadolinium, magnetic resonance imaging, surgical procedure
Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Sep 9, 2026, 5:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

NCT04789486
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas
Interventions
AGuIX, Radiotherapy
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 9, 2026, 5:22 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Prolonged Gadolinium Retention After MRI Imaging

NCT02421029
View directory record Official record
Conditions
Heavy Metal Toxicity
Interventions
edetate calcium disodium
Drug
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
20 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Sep 9, 2026, 5:22 AM EDT
Completed No phase listed Observational

Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)

NCT00773409
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Not listed
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
Not listed
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Sep 9, 2026, 5:22 AM EDT
Terminated Phase 3 Interventional Results available

Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent

NCT02084628
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Gadoxetate disodium (Eovist/Primovist, BAY86-4873)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 2 Months
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

Comparison of Magnetic Resonance Angiography and Standard Angiography in Diagnosing Atherosclerosis

NCT00001946
View directory record Official record
Conditions
Atherosclerosis
Interventions
Magnetic resonance angiography
Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma

NCT02022644
View directory record Official record
Conditions
High Grade Glioma
Interventions
nanoliposomal irinotecan
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009)

NCT03086616
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma
Interventions
Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)
Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
2 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

Motexafin Gadolinium Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma

NCT00003909
View directory record Official record
Conditions
Untreated Childhood Brain Stem Glioma
Interventions
motexafin gadolinium, radiation therapy, pharmacological study
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 9, 2026, 5:22 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

NCT06220669
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
LY3541860, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Gulf Breeze, Florida • Winter Park, Florida • Northbrook, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 9, 2026, 5:22 AM EDT